Interstitial Lung Diseases Clinical Trials
3 recruiting trials for Interstitial Lung Diseases. Eligibility criteria explained in plain English.
TrialFinderData lists 3 Interstitial Lung Diseases clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 3 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Boehringer Ingelheim (1), University of Chicago (1), Aveiro University (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Nerandomilast (drug, 1 trial), followed by Placebo.
Track Interstitial Lung Diseases trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of...
This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred,...
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples...
LetS Get fUnctional! FuNctional Status in pEople With intersTitial Lung Disease
This study aims to i) To characterize the functional status and explore the determinants of functional status decline of people with IlD ii)To determine the measurement properties...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Interstitial Lung Diseases, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Interstitial Lung Diseases, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Interstitial Lung Diseases, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.